Research

Hormonal

Chronic administration of the dual beta-2/beta-3 adrenergic agonist ATR-127 significantly reduces body weight and fat mass while improving glucose homeostasis in diet-induced obese mice, without causing cardiac hypertrophy.

This research suggests that a specific drug targeting fat and muscle metabolism (ATR-127) can reduce body fat and improve blood sugar control in obese individuals without harming the heart, a common side effect of older weight-loss drugs. This is currently only proven in mice and lab cells, so it is not yet available for human use.

ModerateSupportsMEDIUM confidence
After 21 days of treatment, both body weight and fat mass were significantly reduced (p < 0.0001, Figure 4G-H), whereas no significant differences were observed in lean mass... Chronic ATR-127 treatment (5 mg/kg/day for 21 days) did not affect heart weight in DIO mice, indicating that cardiac hypertrophy did not occur.
Emanuela Talamonti et al. · Molecular Metabolism · 2024

Why this rating

The evidence is derived from preclinical animal models (mice) and in vitro human cell lines, not human clinical trials.

Source

The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis

Emanuela Talamonti et al. · Molecular Metabolism · 2024

DOI 10.1016/j.molmet.2024.101931

mechanism_only · n=8Cited 10×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →